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Abstract
In clinical practice and in research, there is an ongoing debate on how to return incidental
and secondary findings of genetic tests to patients and research participants. Previous
investigations have found that most of the people most of the time are in favor of full disclo-
sure of results. Yet, the option to reject disclosure, based on the so-called right not to know,
can be valuable especially for some vulnerable subgroups of recipients. In the present study
we investigated variations in informational preferences in the context of genetic testing in a
large and diverse German sample. This survey examined health care professionals,
patients, participants of genetic counseling sessions and members of the general population
(N = 518). Survey participants were assessed regarding their openness to learning about
findings under various hypothetical scenarios, as well as their attitudes about the doctor-
patient-relationship in a disclosure situation and about informational transfer to third parties.
While the majority of participants wanted to learn about their findings, the extent of support
of disclosure varied with features of the hypothetical diagnostic scenarios (e.g., controlla-
bility of disease; abstract vs. concrete scenario description) and demographic characteris-
tics of the subjects. For example, subjects with higher levels of education were more
selective with regards to the kind of information they want to receive than those with lower
levels of education. We discuss implications of these findings for the debate about the right
not to know and for the clinical practice of informed consent procedures.
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Introduction
The rapidly increasing use of high throughput genome sequencing techniques in medicine is
accompanied by a similarly increasing number of ethical and juridical questions. Of particular
importance is the implementation of high throughput procedures in clinical practice [1,2],
where it can be used for various purposes (e.g., to individualize treatment by predicting a
patient’s tolerance of different medication options). Nowadays, the entire human genome can
be sequenced and analyzed rapidly at ever-decreasing costs. Such high-throughput methods
are very likely to produce incidental findings [3]. The American College of Medical Genetics
and Genomics (ACMG) defines incidental or additional findings as “. . .results of a deliberate
search for pathogenic or likely pathogenic alterations in genes that are not apparently relevant
to a diagnostic indication for which the sequencing test was ordered [. . .] but that may none-
theless be of medical value or utility to the ordering physician and the patient” [4]. Secondary
findings are defined as findings that are “actively sought by a practitioner that is not the pri-
mary target” (Presidential Commission for the Study of Bioethical Issues, 2013).
Incidental or secondary findings bear the potential for ethical and psychological conflict, as
the disclosure of unexpected and potentially disturbing information can lead to considerable
psychological discomfort. The obligation of healthcare professionals to fully inform patients
about their health status might clash with the patients’ right to informational self-determina-
tion, involving the so-called “right not to know” which grants people the right not to be con-
fronted with unwanted information about their personal matters [5]. An important question is
thus how practitioners should deal with the existence of such additional information.
Ethicists, clinicians and lawyers offer answers and recommendations that range from never
disclosing anything that was not intended, to disclosing every finding [6–9]. Central issues in
this discussion are the clinical and personal utility of incidental or secondary findings. Poten-
tial positive consequences, e.g. behavioral changes benefitting health [10], and negative conse-
quences, e.g. psychological harm [11,12], of a disclosure of incidental findings have been
discussed. Furthermore, the ongoing debate tries to formulate different rules and procedures
for contexts with different goals (e.g., research vs. clinical) [13]. Regarding the research con-
text, Ramoni et al. found that just a few investigators (about 4%) had experience in returning
individual results, but that the majority stated that return of results is appropriate under at
least some circumstances [14]. Evans and Rothschild argued for a minimum obligation to dis-
close incidental findings in research [15]. Concerning the clinical setting, in 2013 the ACMG
provided a minimum list of 56 genetic mutations which are actionable that must be disclosed
in the clinical setting, regardless of the patient’s preference [4]. In consequence of critical reac-
tions (Presidential Commission for the Study of Bioethical Issues, 2013) the statement was
revised in 2016 to a list including “59 medically actionable genes recommended for return in
clinical genomic sequencing”, which are no longer mandatory [16]. In 2004, the German Fed-
eral Parliament implemented the ‘right not to know’ in the law and described it as manifesta-
tion of the right of informational self-determination (Genetic Diagnosis Act, 2004). In sum,
despite considerable controversy about its adequate implementation and its limits, the general
importance of the right not to know is not under dispute today.
Informational preferences in the context of genetic testing
The necessity to formulate a right not to know arises when people prefer ignorance over full
information about their personal matters. When and to what extent people have such a prefer-
ence for ignorance are empirical questions that can be assessed with methods from the social
sciences. Even though data on people’s informational preferences cannot tell us directly which
social regulations we should implement (“no ought from an is”), they might nonetheless
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provide fruitful input for the normative debate outlined above. For example, they might serve
to estimate the subjective importance of the existence of a right not to know for different
groups of people, or to delineate the conditions under which a failure to enforce such a right
might be especially consequential.
Recent research in cognitive psychology suggests that people often prefer ignorance over
full information [17–19]. For example, a recent study found that 85–90% would not want to
know in advance which negative events would strike them in the future (e.g., cause of death,
divorce) [17]. However, the preference for ignorance with regards to potentially threatening
upcoming life events seems to be less pronounced in the context of genetic testing. Several
studies demonstrate that genetic testing is generally evaluated positively in the public [20]. It
has been shown that the majority wants to learn about their results and that there is almost no
difference between risk information (e.g., information about carrier status) and information
about a secured diagnosis (e.g., onset of dementia) [21–26]. Whereas experts emphasize clini-
cal utility as decision criterion for disclosure [27], participants mention that they would also
personally benefit from genetic information without clinical relevance [28–30]. Analyzing
time trends within public attitudes, a comparison between 2002 and 2010 showed that people
in 2010 anticipated more use of genetic information and were more interested in their genetic
make-up, but also expected more social discrimination in the context of genetic testing com-
pared to participants in 2002 [31].
Despite this general picture, some studies have discovered important moderators for peo-
ple’s interest in learning about their results. As can be expected, this interest seems to drop
considerably when the results concern uncontrollable as compared to preventable diseases.
For instance, 88% of a Canadian sample with patients who were at high risk for developing
Huntington’s disease did not participate in a predictive test [32]. Yaniv and Sagi used hypo-
thetical scenarios and found that about 50% of their participants did not want to receive geno-
mic information about their healthcare status regarding Huntington’s disease. As reasons for
not wanting to know participants mentioned ‘lack of treatment’ and ‘anxiety, depression and
stress’ [33]. Melnyk and Shepperd showed that lacking coping resources, anticipated regret
und reading about uncontrollable predictors are associated with avoidance of risk information
about breast cancer [34]. In another study, the concrete decision on wanting genomic infor-
mation in hypothetical scenarios presenting cases of devastating late-onset diseases was pre-
dictable through explicit features of the disease scenario, namely the ‘controllability of the
disease’ and the ‘power of the test’ [35].
Some studies found additional moderators next to controllability. Henneman and col-
leagues surveyed the attitudes towards genetic testing of a Dutch sample and identified oppo-
nents (30%) and supporters (32%) of genetic testing. Being a supporter was related to the belief
in benefits of testing and being confident that genetic information might help in establishing a
healthy lifestyle. Opponents were more likely to believe that genetic testing is tampering with
nature. Demographic variables as level of education, gender and age were not associated with
being opponent or supporter [36]. In a Russian sample 85% of 2000 participants were inter-
ested to undergo predictive genetic testing for preventable (controllable) health conditions.
The factors most strongly related to a high level of interest were willingness to improve one’s
lifestyle and overestimated expectation towards genetic testing [37]. A survey in Finland
showed that the majority approved of genetic tests and stressed positive consequences. Inter-
estingly, participants with the highest level of genetic knowledge took more extreme positions
(enthusiasm and skepticism) [38].
In sum, the general picture of the previous findings depicts high levels of interest in learning
about potentially disturbing results of genetic tests, but that there are also important boundary
conditions that significantly reduce openness to such information. In the present study, our
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main aim is to broaden the database on people’s informational preferences in the context of
genetic testing by investigating a large and diverse German sample. We focus on the openness
towards the receipt of genetic findings in different hypothetical diagnostic scenarios with var-
ied availability of prevention and/or intervention options (e.g. breast cancer, Chorea Hunting-
ton). Furthermore, we investigate preferences regarding doctors’ behavior in a disclosure
situation and informational transfer to third parties (e.g. insurance companies). Subsequently,
we take an exploratory look at demographic characteristics that might be associated with infor-
mational preferences regarding the disclosure of incidental or secondary findings. Previous
research indicates that prior experience with genetic tests (either as patient or healthcare pro-
fessional) might be especially important [9,25,27,38,39]. In addition, we conducted exploratory
analyses of how our participants’ gender and educational level relates to their attitudes. We
conclude by discussing the implications of our findings for the practice of pre-test counseling
and by outlining open questions for future research.
Materials and methods
Participants and assessment procedure
523 participants completed the questionnaire assessing the ‘normative foundation and practi-
cal validity of the right not to know’ (www.recht-auf-nichtwissen.uni-goettingen.de). The ques-
tions were developed in discussions with experts of the field of genetic, psychiatric and
juridical research and based on literature research. A pilot study including an interview with a
human geneticist unrelated to the project was conducted to ensure the comprehensibility and
quality of the questionnaire. The questionnaire was approved by the ethics committee of the
University of Go¨ttingen Medical Center (reference number 20/1/13; for further information
about the approval process, see www.ethikkommission .med.uni-goettingen.de). The final ver-
sion of the questionnaire consists of 53 items (see S1 File).The survey was conducted via a
paper-pencil (N = 335) and an online-version (N = 188). Paper-pencil questionnaires were
mainly completed by individuals seeking genetic counseling, patients, and healthcare profes-
sionals at the University of Go¨ttingen Medical Center. The material was distributed by provid-
ing questionnaires in the clinic’s waiting rooms or at notice-boards in the area of the Medical
Center of the University of Go¨ttingen. Interested participants were encouraged to send com-
pleted questionnaires back to the Institute of Medical Law or to directly transfer it to medical
staff. Additional questionnaires were distributed in other locations in Go¨ttingen (e.g. adminis-
trative bodies, resident physicians, notice-boards, etc.). The online survey was published via
newsletters and homepages (e.g. German Association for Bipolar Disorder (DGBS), The Ger-
man Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN), University of
Go¨ttingen Medical Center). Data were collected from June 2014 to November 2014. No per-
sonally identifying data were collected, and the participants took part in the survey voluntarily.
Five participants (three paper-pencil, two online) reported an age under 18 years and were
therefore excluded from the analyses. Characteristics of the remaining sample (N = 518) are
summarized in Table 1. Comparing the demographic variables with regard to the recruitment
procedure, the online version reached more highly educated subjects and more subjects with a
professional role in the health care system than the paper-and-pencil version.
Instruments
The questionnaire consisted of 53 multiple-choice items and examined participants’ attitudes
towards different areas concerning medical findings. First, demographic variables were col-
lected. Participants were asked about their role in the healthcare-system and to what extent
they or their family members suffered from genetic or other severe diseases (e.g. psychiatric
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disease). In the subsequent sections, the participants were asked about their general attitudes
towards incidental and secondary findings and the use of personal health data. This section
was followed by hypothetical diagnostic scenarios in which clinically relevant findings were
presented and participants could decide if they are in favor of learning this information or not.
We varied the disorder (e.g. dementia, breast cancer), the consequences of having that disorder
(e.g. wheel chair, morbidity), age and certainty of outbreak (e.g. risk information), context of
disclosure (e.g. clinical vs. research context), and availability of treatment or prevention. The
next section examined attitudes towards the doctor-patient relationship, focusing on the par-
ticular ethical concepts of autonomy and duty of care. Participants were asked for their prefer-
ences concerning the doctor´s behavior in the case of an incidental or secondary finding (e.g.
if it is reasonable to override someone´s wish not to know in case that a severe and actionable
finding has been found). The final section asked about attitudes towards diagnostic scenarios
involving third parties (e.g. offspring, other relatives, or insurance companies). The questions
focus on the openness towards information transfer to third parties and on perceived obliga-
tions of others to conduct genetic tests (e.g. pilots, partners). Parts of the questionnaire were
based on the GenEthics Questionnaire and modified by members of the BMBF project group
“Normative fundament of the right not to know” [16]. For the detailed questionnaire, see sup-
porting information (S1 File).
Table 1. Descriptive measures of the sample.
Demographic variable Descriptive statistics (N = 518)
Age M = 42.5, SD = 13.9 (range 18–77)
Sex
Male 30.6% (N = 147)
Female 69.4% (N = 334)
Educational level
12–13 years of school 55.9% (N = 279)
10 years of school 25.5% (N = 127)
9 years of school 15.0% (N = 75)
Other 3.6% (N = 18)
Religion
Catholic 22.9% (N = 115)
Protestant 40.4% (N = 203)
No confession 32.0% (N = 161)
Other 4.8% (N = 24)
Professional role in the healthcare system
Physician 7.3% (N = 35)
Nurse 4.4% (N = 21)
Medical student 2.5% (N = 12)
Other 21.0% (N = 101)
None 64.8% (N = 311)
Level of being affected by somatic genetic disorder
Themselves 13.8% (N = 71)
Family members 23.0% (N = 119)
Themselves and family members 11.1% (N = 57)
Not affected 52.0% (N = 268)
Affected by psychiatric disorder 13.9% (N = 72)
https://doi.org/10.1371/journal.pone.0198249.t001
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Statistical analysis
Statistical analyses were performed with the software package SPSS (IBM Corp. Released 2013.
IBM SPSS Statistics for Windows, Version 22.0., Armonk, NY: IBM Corp). To compare atti-
tudes of different groups (e.g. professionals vs. general population) chi-square analyses were
carried out. Items that were assessed with a continuous scale were dichotomized according to
whether participants qualitatively indicated agreement or disagreement prior to analysis. Indi-
cations of indifference were assigned to the “I don’t know” category.
Results
The results section is structured as follows. In the first sub-section we present descriptive
results regarding informational preferences across the entire sample to convey a descriptive
impression of the attitudes of our subjects. We follow the structure of the questionnaire by dis-
playing results concerning the wish to know or not to know, the attitudes towards the doctor-
and patient relationship, and the preferences regarding informational transfer to third parties.
In the second sub-section we take a closer look at the demographic factors potentially associ-
ated with informational preferences (being affected personally, gender, educational level, pro-
fessional role in the healthcare system).
Informational preferences across the entire sample
The wish to know. Ninety-one percent of our participants agreed with the statement that
everybody had the right to know everything about her or his genetic disposition including
risks and carrier status information for genetic diseases. Eighty-two percent wanted to learn
about every incidentally found disease. In case of an incidentally found risk of a genetic dis-
ease, 66% wanted to be informed about that. Forty-eight percent would participate in a genetic
test for 250 potential disorders, if there were an accessible and affordable option to test. When
a specific description of disease and possible ways of intervention or/and prevention were pre-
sented, 80% of the respondents wanted to know if they had a genetic precondition for heart
attack (no special intervention available). Disclosure of information about a precondition for
breast cancer with options of intervention and prevention was favored by 88% of the partici-
pants. When the scenario shifted to various types of cancer without possibilities of prevention,
this number dropped to 69%. Receiving information about a genetic risk for myatrophy by the
age of 30 to 40 was welcomed by 74%.
In summary, the results show that the majority of the participants wanted to be informed
about potential findings regarding genetic diseases. Despite this openness to information, 75%
agreed with the statement that they would expect to experience emotional distress upon learn-
ing about these conditions. Furthermore, 51% thought that knowledge of these findings could
lead to societal discrimination.
The wish not to know. Being asked about unspecified findings in an abstract way (without
describing a concrete scenario; e.g., “I want to know about any (genetic) disorder I have that is
found incidentally”), 3–4% rejected the disclosure of information. When we asked about the
wish to receive risk information 14% answered they would reject that information. In concrete
scenarios with mention of different findings including diagnosis, consequences, and interven-
tion possibilities, 5% to 25% decided to reject the disclosure of those findings (see Fig 1).
Answers differed with respect to different diagnoses. In case of a risk for reoccurrence of a
depressive episode (i.e., after having suffered from depression before), 5% would reject the dis-
closure, whereas disclosure about a genetic predisposition to cancer would not be welcomed by
25% (further examples: dementia: 10%; heart attack: 17%, breast cancer: 9%, myatrophy: 21%).
The right not to know
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Doctor-patient-relationship with respect to the wish not to know. The third section
examined attitudes towards the extent of the physician’s responsibilities with respect to the
wish to know and not to know. 35% of the respondents agreed with the statement that their
physician should know everything about their genetic health condition and decide him- or
herself which information is disclosed. 68% were of the opinion that, if they had to decide
between the ethical principles of the respect for patient´s autonomy and the physician duty of
care, their autonomy outweighed the medical duty of care. Being asked if the physician should
have the right to ignore the patient’s decision to remain ignorant, 66% were against this type of
behavior and 21% would tolerate that decision only in exceptional cases. These exceptional
cases included cases of life and death and consequences for others.
Third parties. The fourth section examined attitudes toward a potential involvement of
third parties, especially information transfer of a finding. Whereas 85% considered informing
their relatives in case of receiving results that could also affect family members, only 58%
agreed with the statement that they would always want to be informed if their relatives were
affected. Ninety-two percent did not want their insurance companies to have the right to
examine their genetic predisposition. Being asked if individuals with high responsibilities in
their job (e.g. pilots) should have a mandatory genetic sequencing test, 32% approved this idea.
Fifty-five percent of the respondents did not consider it necessary to test their partners with
regard to reproductive concerns. Thirty-seven percent did not want to test themselves in order
to check their reproductive conditions. Thirty-nine percent wished to know if their children
had a genetic precondition for a disease during pregnancy.
Demographic factors associated with informational preferences. In a next step, we
investigated how demographic and phenotypic features (e.g. educational level, gender) were
related to participants‘informational preferences (e.g. towards full disclosure).
Affected versus unaffected individuals. Affected individuals (people with genetic disease
or relatives of ill people) did virtually not differ in any way from non-affected individuals in
our sample.
Fig 1. The wish to know in different diagnostic scenarios.
https://doi.org/10.1371/journal.pone.0198249.g001
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Gender. Of the male participants, 68% revealed that they would take a genetic test to
examine their reproductive conditions whereas only 50% of female participants would take
that test (χ2 (2, N = 461) = 13.5, p< .001). Additionally, men were slightly more motivated to
enroll in a sequencing test for 250 genetic diseases than women (56% of the men and 44% of
the woman agreed, χ2 (2, N = 466) = 5.9, p< .05).
Educational level. The data revealed differences on many items with regard to the educa-
tional level (EL). Detailed information about percentages of agreement split up by EL is dis-
played in Table 2. Respondents with a higher EL (12 to 13 years of school, corresponding to
higher education entrance qualification) were significantly more likely to emphasize the
patient’s autonomy over the physician’s responsibility than participants with a low average EL
(10 years of school) (χ2 (2, N = 480) = 10.3, p< .01). In case of a severe disease without pos-
sibilities for therapy, respondents with high EL were more likely to disapprove of the physi-
cian’s disrespect for an agreed-upon non-disclosure than low-EL respondents (χ2 (2, N = 474)
= 48.0, p< .001). People with low EL wanted their doctor to know and decide everything
regarding their physical condition to a greater extent than participants with higher EL (χ2 (2,
N = 475) = 27.2, p< .001).
The wish to know everything regarding risk factors was significantly less pronounced in
people with high EL (χ2 (3, N = 482) = 20.6, p< .001). In scenarios where a concrete case is
defined, including potential consequences of the disease, people with higher EL were more
likely to reject the disclosure (case hereditary cancer: χ2 (2, N = 484) = 11.8, p =<0.01; case
cardiovascular disease: χ2 (2, N = 481) = 19.0, p< .001). In the group of the people with high
EL, there were significantly more people who did not want their offspring to be tested (χ2 (2,
N = 479) = 9.7, p< .01), nor people with special responsibilities (e.g. pilots; χ2 (2, N = 483) =
31.7, p< .001).
We also asked patients to imagine they were 18 years of age and confronted them with find-
ings of a genetic disease with various ages at disease onset (20 years, 40 years, or 60 years). In
participants with high EL, age at onset had an impact on their desire to learn about their
genetic risk. The later the disease onset, the less highly educated people wanted to know and
the more they could be distinguished from people with low EL (onset at 20 years: χ2 (2,
N = 443) = 5, p = .071; onset at 40 years: χ2 (2, N = 458) = 8.0, p< .01, onset at 60 years: χ2 (2,
N = 465) = 21.0, p< .001). In summary, highly educated people had a tendency to emphasize
the patient’s autonomy and were more likely to reject information resulting from genome
sequencing than less educated people.
Professional role in the healthcare system. Detailed information about percentages of
agreement regarding professional role in the healthcare system is displayed in Table 3. Profes-
sionals rejected disclosure of a hypothetical incidental or secondary finding significantly more
often than participants without such professional background (information about any disease:
χ2 (9, N = 462) = 17.0, p< .05). They objected to receiving a finding or information on risk
more often (χ2 (9, N = 463) = 25.7, p = < .01) and they were less willing to participate volun-
tarily in an inexpensive genetic test (χ2 (6, N = 464) = 15.5, p< .05). Furthermore, they tended
to emphasize the patient’s autonomy in health decisions as opposed to the view that the physi-
cian knows best and should make decisions in a patient’s favor (χ2 (6, N = 461) = 13.2, p<
.05). Also, physicians and medical students were significantly less willing to have themselves or
their children tested in order to examine their reproductive conditions as compared to partici-
pants without a role in the healthcare system (χ2 (6, N = 459) = 16.0, p< .01). In sum, physi-
cians and medical students tended to indicate less interest in medical information disclosure
compared to people outside the health care system.
The right not to know
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Table 2. Percent agreement by educational level for selected items.
Response Options Educational Level Statistics
12–13 years 10 years
Do you want to know if you inherited the genetic predisposition for cardiovascular disease?
yes 76% 85% χ2 (2, N = 481) = 19.0, p< .001
no 23% 10%
I don’t know 1% 5%
Do you want to know if you have inherited the genetic makeup for hereditary cancer?
yes 65% 73% χ2 (2, N = 484) = 11.8, p< .01
no 31% 19%
I don’t know 4% 8%
My physician should know all my genetic findings and decide on the basis of his professional knowledge which he
tells me about and which he doesn’t tell me about.
yes 25% 46% χ2 (2, N = 475) = 27.2, p< .001
no 73% 50%
I don’t know 2% 5%
Which of the following do you think outweighs the other: The physician’s duty of care towards you as a patient or
your right to self-determination?
Duty of care 16% 27% χ2 (2, N = 480) = 10.3, p< .01
Self-determination 74% 61%
I don’t know 10% 12%
Physician overrides your decision not to know in case of risk information about a non-actionable severe disease. Do
you agree?
Yes, I agree 30% 57% χ2 (2, N = 474) = 48.0, p< .001
No, I do not agree 61% 29%
I don’t know 10% 14%
Would you want to know already before the birth whether your child has a genetic risk for a genetic disorder?
yes 34% 45% χ2 (2, N = 479) = 9.7, p< .01
no 60% 46%
I don’t know 6% 9%
Should people who have jobs with special responsibility (e.g. pilots) be tested for certain genetic risks?
yes 25% 41% χ2 (2, N = 483) = 31.7, p< .001
no 67% 42%
I don’t know 8% 17%
I want to know about any risk I have for a genetic disorder that is found incidentally.
yes 57% 77% χ2 (3, N = 482) = 20.6, p< .001
no 19% 11%
Only, if prevention possibilities are available 17% 9%
I don’t know 7% 3%
Depending on the following age of onset of the illness, would you want to know if you have the genetic defect? 20
Years
yes 77% 72% χ2 (2, N = 443) = 5.3, p = .071
no 19% 18%
I don’t know 5% 10%
Depending on the following age of onset of the illness, would you want to know if you have the genetic defect? 40
Years
yes 78% 82% χ2 (2, N = 458) = 8.0, p< .01
no 18% 10%
I don’t know 4% 8%
Depending on the following age of onset of the illness, would you want to know if you have the genetic defect? 60
Years.
(Continued)
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Discussion
Based on a large sample, our study sheds some light on preferences surrounding a person’s
wish to know or not to know and potentially associated factors. Results from previous surveys
of the general population and patients suggest that the overwhelming majority of persons sur-
veyed are in favor of learning about health information and incidental and secondary findings,
and also about raw data on their own health condition [20–23,25,28,29,39]. This general ten-
dency has been replicated in our study. However, even though people seem to be interested in
learning their results and anticipate positive behavioral change [22], the majority of our
Table 2. (Continued)
Response Options Educational Level Statistics
12–13 years 10 years
yes 63% 71% χ2 (2, N = 465) = 21.0, p< .001
no 33% 17%
I don’t know 4% 12%
Note. For reasons of space, the wording of the questions displayed in this table is abbreviated. Please see S1 File for
the exact question wording in the original questionnaire. Percentages might not add up to 100% due to rounding
errors. All reported p-values are Bonferroni corrected.
https://doi.org/10.1371/journal.pone.0198249.t002
Table 3. Percent agreement by professional role in the healthcare system for selected items.
Response Options Professional Role Statistics
Physicians/ Medical Students Nurses Other Role No Role
I want to know about any risk I have for a genetic disorder that is found incidentally.
yes 37% 84% 61% 70% χ2 (9, N = 463) = 25.7,
p = < .01)no 28% 5% 16% 12%
Only, if prevention possibilities are available 24% 11% 14% 14%
I do not know 11% 0% 9% 4%
I want to know about any disease I have that is found incidentally.
yes 65% 81% 81% 85% χ2 (9, N = 462) = 17.0,
p< .05)no 4% 0% 4% 3%
Only, if prevention possibilities are available 24% 14% 10% 11%
I do not know 7% 5% 5% 1%
There is a simple and reasonably priced option to be tested for your risk for more than 250 genetic disorders. Would you get yourself tested?
yes 32% 40% 45% 52% χ2 (6, N = 464) = 15.5,
p< .05)no 60% 40% 47% 34%
I do not know 9% 20% 8% 13%
Would you have yourself genetically tested so you can better assess the risk that (future) children will develop a serious disease?
yes 50% 55% 50% 57% χ2 (6, N = 459) = 16.0,
p< .01)no 48% 20% 44% 36%
I do not know 2% 25% 5% 7%
My physician should know all my genetic findings and decide on the basis of his professional knowledge which he tells me about and which he doesn’t tell me about.
yes 20% 47% 26% 40% χ2 (6, N = 461) = 13.2,
p< .05)no 78% 53% 70% 57%
I do not know 2% 0% 4% 4%
Note. For reasons of space, the wording of the questions displayed in this table is abbreviated. Please see S1 File for the exact question wording in the original
questionnaire. Percentages might not add up to 100% due to rounding errors. All reported p-values are Bonferroni corrected.
https://doi.org/10.1371/journal.pone.0198249.t003
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participants was also of the opinion that genetic testing has the potential for negative conse-
quences (e.g. psychological distress, societal discrimination).
To study informational preferences in-depth, we varied the characteristics of genomic find-
ings and analyzed how this affects the ‘wish to know’. The finding of previous research that
preference for disclosure depends on features of the to-be-diagnosed disease (such as its con-
trollability) [32–34] was replicated in our study. Our results furthermore indicate that the
amount of information given about the potential consequences of an incidental finding
affected the participants’ wish to know (Fig 1). When the question is phrased in an abstract
and reduced way (e.g., “I want to know about any disease I have that is found incidentally”), an
overwhelming majority preferred disclosure of the finding. But when it came to scenarios with
a detailed description of the finding (e.g. name and symptoms of the disease), the percentage
of persons consenting to full disclosure dropped considerably.
Cognitive psychologists have gathered ample evidence that the level of abstraction at which
a situation is represented has profound effects on subsequent judgment and decision-making
[40]. While an abstract construal leads to a focus on the central features of a choice object (e.g.,
the main purpose of a medical test, which is to benefit the recipient), peripheral features (such
as psychological distress that might arise as unintended side-effect in some concrete diagnostic
scenarios) are usually only represented at a more concrete level of construal. This asymmetry
has important implications for the clinical practice of informed consent. If patients consent to
a genetic test while they represent it in a highly abstract fashion, they might underestimate the
extent to which they will be negatively affected when they are actually faced with a concrete
disturbing outcome in the future. We should thus ask ourselves if it is enough to ask patients
or participants whether they want to receive information on incidental or secondary findings
or not. It could be important to mention the possibility of negative consequences. In order to
make an educated decision as to whether one wants to receive information about incidental or
secondary findings one should have the possibility to reflect about a number of potential con-
crete scenarios that can arise from the disclosure (e.g. clinical validity, interpretation of risk
information, potential psychological distress and discrimination).
A study population of over 500 participants drawn from a diverse background (e.g. health-
care professionals, patients, general population) enabled us to compare the views of different
groups. While prior research found that patients want to receive information about incidental
findings more than the general population and health care professionals [39], our data revealed
no differences between individuals who are personally affected and those who are not. Rather,
in our sample the educational level and the professional role in the healthcare system were
most strongly associated to the expressed attitudes. Previous findings showed that experts and
professionals of the healthcare system tend to be more reflected regarding this topic as they
mainly wish to learn results that are actionable [27,30,39]. Our results replicate these findings
in that physicians and medical students tend to be more selective in the kind of information
they want to receive. The same is true more generally for participants with higher levels of
education.
Limitations and outlook
The hypothetical character of the questionnaire has to be discussed. When being confronted
with the questionnaire the participants make a judgment about hypothetical scenarios. Being
in an actual decision situation (a pre-counselling session in clinical or research context) might
lead to a deeper elaboration of the topic. It should be noted, though, that the judgment about
one’s openness towards an incidental or secondary finding in a real clinical scenario is also to
some extent hypothetical in character, as the potentially relevant test results do not (yet) exist
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at the moment of decision. We are therefore confident that our findings have external validity
despite their hypothetical character.
Concerning our sample it is important to be aware that the collection of participants who
completed the paper-and-pencil version of the questionnaire mainly took place in the context
of the Go¨ttingen University Medical Center. The recruitment via online-version was launched
nationwide in different newsletters. The sample is not representative for the whole country, so
the findings cannot be generalized to all German citizens. Our goal was rather to investigate a
sample that is heterogeneous with regards to participants’ involvement with genetic testing (as
patient or practitioner, or without any connection to the subject) to allow for an exemplary
comparison of these groups’ attitudes towards incidental or secondary findings.
Our results showed that the factors ‘professional role in the healthcare-system’ and ‘educa-
tional level’ are associated with these attitudes. Since both factors are likely correlated to each
other and to other potentially explanatory variables that we did not measure (e.g., socio-eco-
nomic status), we cannot conclude from the observed relationships on which of these factors,
if any, participants’ attitudes causally depend. Future research is needed to disentangle the
causal roles and relative contributions of the different predictors. Such studies would require a
more systematic composition of the sample.
In general, this explorative study shows that, while people seem to be generally interested in
learning about personalized genetic information, personal factors and the way in which ques-
tions are posed can lead to different opinions that might potentially result in different deci-
sions. As a conclusion, these factors should be further examined and then be considered in
clinical practice. Clinicians and researchers in the field of genetics have to reflect the way in
which they explain the situation (e.g. abstract question vs. concrete scenario), and they might
have to take the personal situation and background of the individuals in question into account.
The integration of the concept of the ‘right not to know’ with all its ramifications into clinical
and research contexts should follow a thoroughly deliberated fashion, as a kind of ‘disclosure
before disclosure’ that allows recipients to make responsible use of their right to informational
self-determination.
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